-
公开(公告)号:US5902812A
公开(公告)日:1999-05-11
申请号:US693173
申请日:1996-09-24
申请人: Stephen James Brocchini , Justin Stephen Bryans , Adrian John Folkes , Christopher John Latham , Julie Elizabeth Brumwell
发明人: Stephen James Brocchini , Justin Stephen Bryans , Adrian John Folkes , Christopher John Latham , Julie Elizabeth Brumwell
IPC分类号: C07D241/18 , A61K31/495 , A61P7/02 , C07D241/02 , C07D403/10 , C07D405/10
CPC分类号: C07D241/02
摘要: Diketopiperazines of formula (A): ##STR1## wherein each of R.sub.1 to R.sub.8 is H or an organic radical as described herein and the pharmaceutically acceptable salts thereof have activity as inhibitors of plasminogen activator inhibitor.
摘要翻译: PCT No.PCT / GB95 / 00299 Sec。 371日期:1996年9月24日 102(e)1996年9月24日PCT 1995年2月14日提交PCT公布。 出版物WO95 / 21829 日期:1995年8月17日式(A)的二氢哌嗪:其中R 1至R 8各自为H或如本文所述的有机基团,其药学上可接受的盐具有作为纤溶酶原激活物抑制剂抑制剂的活性。
-
公开(公告)号:US5891877A
公开(公告)日:1999-04-06
申请号:US693172
申请日:1996-09-25
申请人: Stephen James Brocchini , Justin Stephen Bryans , Adrian John Folkes , Christopher John Latham , Julie Elizabeth Brumwell
发明人: Stephen James Brocchini , Justin Stephen Bryans , Adrian John Folkes , Christopher John Latham , Julie Elizabeth Brumwell
IPC分类号: C07D241/02 , C07D241/18 , C07D401/06 , C07D401/12 , C07D405/06 , C07D409/06 , C07D521/00 , A61K31/495 , A61K31/535 , C07D241/08
CPC分类号: C07D241/02 , C07D231/12 , C07D233/56 , C07D241/18 , C07D249/08 , C07D401/06 , C07D401/12 , C07D405/06 , C07D409/06
摘要: Diketopiperazines of the formula ##STR1## where one or both of R.sub.1 and R.sub.2, which are different, are chosen from X and a phenyl group substituted by X, C(O)X, OC(O)CH.sub.2 X, OCH.sub.2 CH.sub.2 X, CH.sub.2 X, CONH(CH.sub.2).sub.n X, O(CH.sub.2).sub.n CH(OH)(CH.sub.2).sub.n X ##STR2## and, where appropriate, the other of R.sub.1 and R.sub.2 is a phenyl group optionally substituted by one or more groups selected from halogen, nitro, methoxy, NHC(O)R.sub.12, CO.sub.2 H, O(CH.sub.2).sub.n N(R.sub.12 R.sub.13), C.sub.1 -C.sub.4 alkyl and (CH.sub.2).sub.n C(O)OR.sub.12 ; X is a five- or six-membered heterocyclic ring selected from the group consisting of pyridyl, imidazolyl, furyl, pyrrolyl, pyrrolidinyl, thienyl, piperazinyl, piperidinyl, morpholinyl, quinolyl, isoquinotyl and indolyl, the heteroatom(s) of the said heterocyclic ring, when nitrogen, being optionally substituted by hydrogen, methyl, oxygen, tertiary-butyloxycarbonyl, or SO.sub.2 Me, the heterocyclic ring being optionally substituted by halogen �hydrogen!, methyl, MeS, phenyl, O(CH.sub.2).sub.n N(R.sub.12 R.sub.13) or optionally containing one or more carbonyl groups and being optionally fused to a benzene ring; Y is O or S; R.sub.12 and R.sub.13, which may be the same or different, are hydrogen or C.sub.1 -C.sub.6 alkyl; and n is 0 or an integer having the value 1, 2, 3 or 4; a pharmaceutically acceptable salts or esters having activity as inhibitors of plasminogen activator inhibitor.
摘要翻译: PCT No.PCT / GB95 / 00302 Sec。 371日期1996年9月25日 102(e)日期1996年9月25日PCT提交1995年2月14日PCT公布。 出版物WO95 / 21832 日期为1995年8月17日,由X,C(O)X,OC(O)CH 2 X,OCH 2 CH 2 X,CH 2 X,CONH(CH 2)n X,O( CH 2)n CH(OH)(CH 2)n X
,并且在适当的情况下,R 1和R 2中的另一个是任选被一个或多个选自卤素,硝基,甲氧基,NHC(O)R 12,CO 2 H ,O(CH 2)n N(R 12 R 13),C 1 -C 4烷基和(CH 2)n C(O)OR 12; X是选自吡啶基,咪唑基,呋喃基,吡咯基,吡咯烷基,噻吩基,哌嗪基,哌啶基,吗啉基,喹啉基,异喹啉基和吲哚基的五元或六元杂环,所述杂环的杂原子 环,任选地被氢,甲基,氧,叔丁氧基羰基或SO 2 Me取代,杂环任选被卤素[氢],甲基,MeS,苯基,O(CH 2)n N(R 12 R 13)或任选地被 含有一个或多个羰基并任选地与苯环稠合; Y为O或S; R 12和R 13可以相同或不同,是氢或C 1 -C 6烷基; 并且n为0或具有值1,2,3或4的整数; 具有作为纤溶酶原激活物抑制剂抑制剂活性的药学上可接受的盐或酯。 -
公开(公告)号:US5861400A
公开(公告)日:1999-01-19
申请号:US693169
申请日:1996-11-04
IPC分类号: C07D241/02 , C07D401/06 , C07D403/06 , C07D405/06 , C07D409/06 , A61K31/495
CPC分类号: C07D241/02 , C07D401/06 , C07D403/06 , C07D405/06 , C07D409/06
摘要: Piperazine derivatives of the formula ##STR1## their esters and salts are useful as modulators of multiple drug resistance.
摘要翻译: PCT No.PCT / GB95 / 00301 Sec。 371日期:1996年11月4日 102(e)日期1996年11月4日PCT提交1995年2月14日PCT公布。 公开号WO95 / 21831 日期1995年8月17日公式为“IMAGE”(Aa)的哌嗪衍生物,其酯和盐可用作多种耐药性的调节剂。
-
公开(公告)号:US5750530A
公开(公告)日:1998-05-12
申请号:US750020
申请日:1996-12-17
IPC分类号: C07D241/02 , A61K31/495 , A61P7/02 , A61P43/00 , C07D403/06 , C07D405/06 , C07D409/06 , C07D409/14 , C07D401/00 , C07D403/00
CPC分类号: C07D403/06 , C07D405/06 , C07D409/06 , C07D409/14
摘要: A diketopiperazine of formula (I): ##STR1## wherein each of R.sub.7 and R.sub.8 which may be the same or different; is hydrogen or a nitro group; Y is ##STR2## --O-- or --S--, wherein each of R.sub.9 and R.sub.10 which may be the same or different, is hydrogen or a nitro group; n is 0, 1 or 2; m is an integer of 1 to 6; each R.sub.6, which may be the same or different, is a C.sub.1 -C.sub.6 alkyl group; and X is selected from (i) a phenyl group of the following formula ##STR3## and the salts and esters thereof; have activity as inhibitors of plasminogen activator inhibitor.
摘要翻译: PCT No.PCT / GB95 / 01180 Sec。 371日期1996年12月17日第 102(e)日期1996年12月17日PCT提交1995年5月24日PCT公布。 公开号WO95 / 32190 日期:1995年11月30日A式(I)的二酮哌嗪:其中R 7和R 8各自可以相同或不同; 是氢或硝基; Y是-O-或-S-,其中可以相同或不同的R 9和R 10各自是氢或硝基; n为0,1或2; m为1〜6的整数。 每个R 6可以相同或不同,是C 1 -C 6烷基; 并且X选自(i)下式的苯基作为纤溶酶原激活物抑制剂的抑制剂的活性。
-
5.
公开(公告)号:US06218393B1
公开(公告)日:2001-04-17
申请号:US09284642
申请日:1999-06-09
申请人: Hamish Ryder , Philip Anthony Ashworth , Michael Bryan Roe , Julie Elizabeth Brumwell , Sukhjit Hunjan , Adrian John Folkes , Jason Terry Sanderson , Susannah Williams , Levi Michael Maximen
发明人: Hamish Ryder , Philip Anthony Ashworth , Michael Bryan Roe , Julie Elizabeth Brumwell , Sukhjit Hunjan , Adrian John Folkes , Jason Terry Sanderson , Susannah Williams , Levi Michael Maximen
IPC分类号: C07D21704
CPC分类号: C07D401/12 , C07D215/54 , C07D217/04 , C07D405/12 , C07D409/12 , C07D409/14
摘要: Anthranilic acids of formula (I): wherein each of R to R9 is an organic substituent, n is 0 or 1, m is 0 or an integer of 1 to 6, q is 0 or 1, X is a direct bond, O, S, —S—(CH2)p or —O—(CHO2)p— wherein p is from 1 to 6 and Ar is an unsaturated carbocyclic or heterocyclic group, and the pharmaceutically acceptable salts thereof, have activity as inhibitors of P-glycoprotein and may thus be used, inter alia, as modulators of multidrug resistance in the treatment of multidrug resistant cancers, for example to potentiate the cytotoxicity of a cancer drug.
摘要翻译: 式(I)的邻氨基苯甲酸:其中R至R9各自为有机取代基,n为0或1,m为0或1至6的整数,q为0或1,X为直接键, S,-S-(CH 2)p或-O-(CHO 2)p - ,其中p为1至6,Ar为不饱和碳环或杂环基团及其药学上可接受的盐,具有作为P-糖蛋白抑制剂的活性 因此可以特别地用作治疗多药耐药性癌症的多药耐药性的调节剂,例如增强癌症药物的细胞毒性。
-
公开(公告)号:US20110053935A1
公开(公告)日:2011-03-03
申请号:US12864112
申请日:2009-01-26
IPC分类号: A61K31/4709 , C07D401/04 , C07D413/14 , C07D417/14 , C07D401/14 , A61K31/5377 , A61K31/496 , A61K31/506 , A61P35/00 , A61P9/00 , A61P37/00 , A61P27/02
CPC分类号: C07D401/04 , C07D413/14 , C07D417/04 , C07D417/14
摘要: Fused pyridines of formula (I) and the pharmaceutically acceptable salts thereof have activity as inhibitors of c-Met and may thus be used to treat various diseases and disorders including cancer. Processes for synthesizing the compounds are also described.
摘要翻译: 式(I)的稠合吡啶和其药学上可接受的盐具有作为c-Met的抑制剂的活性,因此可用于治疗包括癌症在内的各种疾病和病症。 还描述了合成化合物的方法。
-
-
-
-
-